Aldeyra to run an­oth­er tri­al for its dry eye dis­ease drug as part of re­sub­mis­sion plans

Aldeyra Ther­a­peu­tics is plan­ning to re­sub­mit an NDA for its dry eye dis­ease drug in the sec­ond half of this year, though it’ll have to run an­oth­er clin­i­cal tri­al.

The com­pa­ny said Thurs­day that the re­sub­mis­sion for re­prox­alap is con­tin­gent on pos­i­tive da­ta from an­oth­er dry eye cham­ber clin­i­cal tri­al that is set to start by June. Once Aldeyra re­sub­mits the NDA, the FDA’s re­view pe­ri­od is ex­pect­ed to be six months, rep­re­sent­ing about a 12-month de­lay to the orig­i­nal launch plans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER